Medical Incubator Japan

Investment approach

Thesis

Even if we invest in a venture with unprecedented technology, our investment cannot be called a success unless that technology is actually delivered to patients as treatment. Since it is an investment, we must achieve the target capital gains, but since it is healthcare, it is meaningless unless it benefits patients. To be useful to people through investment: this idea is the foundation of the investment philosophy of the company MIJ. MIJ discovers, invests in and supports the development of healthcare venture companies in Japan and abroad that have cutting-edge technology capable of changing conventional medical common sense, aiming to bring new value to the patients and medical professionals who need it. As a result, we will share the fruits of mutual prosperity with all the investors and partners who cooperated in this investment and development support.Source (opens in a new tab)

Eligibility

投資対象企業 ・再生医療、遺伝子治療等の最新技術から低分子領域まで、ファーストインクラスまたはベストインクラスの医薬品を開発する国内外のスタートアップ企業 ・医療サービスの提供に革新をもたらすデバイスやデジタルヘルスサービスを開発する国内外のスタートアップ企業 投資対象地域 英国、イスラエルを中心とした欧州、北米及び日本 投資ステージ シードラウンド後期、シリーズAラウンド、シリーズBラウンドを中心に検討

Investing status notes

Cytospire Therapeutics Limitedへ投資しました